SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Emcure gets nod to market Poviztra for treatment of non-cirrhotic MASH

21 Jul 2026 Evaluate

Emcure Pharmaceuticals has secured Central Drugs Standard Control Organization's (CDSCO) approval to market Poviztra for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (F2-F3). The Poviztra is Emcure’s co-marketed brand of innovator semaglutide (rDNA origin). It enables Emcure and its subsidiaries to offer the new indication through Poviztra, expanding access to innovator semaglutide for patients living with a progressive liver disease that has long faced limited treatment options.

Poviztra contains innovator semaglutide (rDNA-origin) that has already established its role in chronic weight management in persons living with obesity and are overweight with co-morbid conditions (example Hypertension, Dyslipedemia, Type 2 Diabetes,etc). Poviztra is also approved and marketed already for obese patients with established cardiovascular disease as well as more recently for management of adolescent obesity with pediatric patients above 12 years and above. The addition of the MASH indication for Poviztra further strengthens the company's commitment to addressing complex metabolic diseases through innovative, science-led therapies while supporting physicians in improving long-term patient outcomes.

Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.

Emcure Pharma Share Price

1890.95 -31.45 (-1.64%)
22-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1942.95
Dr. Reddys Labs. 1183.00
Cipla 1415.10
Lupin 2405.80
Zydus Lifesciences 1129.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: